Profile data is unavailable for this security.
About the company
Shanghai Junshi Biosciences Co Ltd is a China-based company primarily engaged in the discovery, development and commercialisation of innovative drugs. The Company’s products primarily include TUOYI toripalimab, recombinant humanized anti-tumor anti-B-and T-lymphocyte attenuator (BTLA) monoclonal Tifcemalimab, MINDEWEI deuremidevir hydrobromide tablets, JUNMAIKANG adalimumab, JUNSHIDA ongericimab, programmed death-1 (PD-1) monoclonal antibody subcutaneous injection formulation and others. The products are primarily used to treat malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. The Company primarily operates its businesses in the domestic and American markets.
- Revenue in CNY (TTM)2.48bn
- Net income in CNY-949.86m
- Incorporated2012
- Employees2.67k
- LocationShanghai Junshi Biosciences Co Ltd16F, Building 7, No. 6, Lane 100Pingjiaqiao Road, Pudong New AreaSHANGHAI 201203ChinaCHN
- Phone+86 2 161058800
- Fax+86 2 161757377
- Websitehttps://www.junshipharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 742.28m | -133.34m | 25.40bn | 910.00 | -- | 22.10 | -- | 34.22 | -0.5038 | -0.5038 | 2.80 | 4.34 | 0.2482 | 0.446 | 4.77 | 815,689.40 | -4.56 | -17.15 | -8.23 | -25.89 | 89.95 | 93.14 | -18.36 | -118.33 | 1.72 | -- | 0.4949 | -- | 37.91 | -- | 50.52 | -- | 44.66 | -- |
| Kangmei Pharmaceutical Co Ltd | 5.28bn | 16.64m | 26.69bn | 4.23k | 1,678.26 | 3.71 | -- | 5.06 | 0.0012 | 0.0012 | 0.3973 | 0.5197 | 0.3785 | 1.64 | 2.23 | 1,246,204.00 | 0.1368 | -21.82 | 0.2232 | -42.17 | 17.12 | -92.73 | 0.3614 | -108.18 | 0.7875 | -- | 0.0162 | -- | 6.47 | -14.63 | -91.64 | -- | -33.46 | -- |
| Xiamen Amoytop Biotech Co Ltd | 3.34bn | 939.58m | 28.11bn | 2.42k | 29.81 | 9.31 | -- | 8.41 | 2.31 | 2.31 | 8.22 | 7.40 | 1.03 | 0.8127 | 4.99 | 1,379,284.00 | 29.05 | 22.72 | 33.93 | 26.54 | 92.37 | 91.62 | 28.11 | 23.51 | 3.20 | -- | 0.0448 | 28.80 | 34.13 | 31.02 | 49.00 | 66.70 | 41.17 | 90.06 |
| Bluestar Adisseo Co | 17.09bn | 1.19bn | 30.80bn | 2.93k | 22.49 | 1.59 | -- | 1.80 | 0.4447 | 0.4447 | 6.37 | 6.31 | 0.7204 | 5.30 | 8.18 | 5,834,541.00 | 5.03 | 5.20 | 6.05 | 6.63 | 27.69 | 29.69 | 6.99 | 8.12 | 1.12 | 10.31 | 0.1377 | 30.01 | 17.83 | 6.88 | 2,208.66 | 3.95 | 5.53 | -7.02 |
| Humanwell Healthcare Group Co Ltd | 24.18bn | 1.43bn | 30.87bn | 17.65k | 21.63 | 1.63 | -- | 1.28 | 0.8741 | 0.8741 | 14.84 | 11.59 | 0.6519 | 3.63 | 2.48 | 1,369,715.00 | 5.00 | 6.40 | 8.73 | 12.55 | 44.53 | 43.83 | 7.67 | 9.90 | 1.40 | 362.14 | 0.2889 | 25.97 | 3.71 | 3.13 | -37.70 | 11.15 | 4.75 | 56.54 |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 5.37bn | 3.58bn | 31.26bn | 3.84k | 10.03 | 3.99 | -- | 5.83 | 4.65 | 4.65 | 6.98 | 11.70 | 0.4758 | 1.35 | 3.16 | 1,399,130.00 | 31.64 | 11.74 | 45.06 | 16.76 | 64.27 | 42.04 | 66.50 | 14.81 | 2.33 | -- | 0.0056 | 54.04 | -11.14 | 0.8791 | 125.94 | 28.94 | -10.54 | 33.67 |
| Shanghai Junshi Biosciences Co Ltd | 2.48bn | -949.86m | 32.48bn | 2.67k | -- | 5.90 | -- | 13.08 | -0.96 | -0.96 | 2.51 | 6.05 | 0.2203 | 0.8436 | 5.48 | 963,148.80 | -9.45 | -17.61 | -12.31 | -22.00 | 81.59 | 68.46 | -42.92 | -84.56 | 1.43 | -23.04 | 0.3629 | -- | 29.67 | 20.24 | 43.90 | -- | -4.33 | -- |
| Beijing Tiantan Biological Products Corp | 6.42bn | 1.32bn | 32.63bn | 5.30k | 24.79 | 2.85 | -- | 5.08 | 0.6656 | 0.6656 | 3.25 | 5.80 | 0.4002 | 0.9382 | 11.21 | 1,212,453.00 | 11.25 | 11.93 | 16.06 | 16.79 | 45.65 | 50.69 | 28.10 | 29.69 | 3.08 | -- | 0.0152 | 16.24 | 16.44 | 12.94 | 39.58 | 20.45 | 15.19 | 23.56 |
| Sunshine Guojian Pharmcutcl Shngh Co Ltd | 1.37bn | 870.39m | 37.38bn | 995.00 | 43.14 | 6.32 | -- | 27.28 | 1.40 | 1.40 | 2.21 | 9.56 | 0.186 | 1.54 | 4.55 | 1,377,045.00 | 11.66 | 3.14 | 15.35 | 3.34 | 74.88 | 77.37 | 62.65 | 16.95 | 1.97 | -- | 0.00 | 12.57 | 17.70 | 0.2733 | 139.15 | 25.17 | 16.61 | -- |
Data as of Feb 11 2026. Currency figures normalised to Shanghai Junshi Biosciences Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
17.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Asset Management Co., Ltd.as of 31 Dec 2024 | 35.30m | 5.27% |
| E Fund Management Co., Ltd.as of 31 Dec 2024 | 22.45m | 3.35% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 10.47m | 1.56% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 8.91m | 1.33% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 8.80m | 1.31% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 7.72m | 1.15% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 6.39m | 0.95% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 6.00m | 0.90% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 5.29m | 0.79% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2025 | 4.30m | 0.64% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
